Mineralcorticoid receptor antagonists for the treatment of endometriosis
OA: closed
AI-generated summary
This invention describes mineralcorticoid receptor antagonists as therapeutic agents for the treatment of endometriosis, offering an improved effectiveness profile and side effect safety by preventing bone mass loss.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and/or profile of side effects than previously available treatment therapies. With a mineralcorticoid receptor antagonist, endometriosis can be lastingly treated without resulting in a loss of bone mass.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-23T06:15:12.370321+00:00